Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma.

@article{Babashov2017EconomicEO,
  title={Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma.},
  author={Vusal Babashov and Mehmet A. Begen and Joy E Mangel and Gregory S. Zaric},
  journal={Current oncology},
  year={2017},
  volume={24 1},
  pages={e6-e14}
}
BACKGROUND We conducted a cost-effectiveness analysis of brentuximab vedotin for the treatment of relapsed and refractory Hodgkin lymphoma (hl) in the post-autologous stem-cell transplantation (asct) failure period, from the perspective of the Canadian health care payer. METHODS We developed a decision-analytic model to simulate lifetime costs and benefits of brentuximab vedotin compared with best supportive care for the treatment of patients with hl after failure of asct. Administrative data… CONTINUE READING